Overview

* Becton Dickinson ( BDX ) Q4 revenue grows 8.3%, adjusted EPS beats analyst expectations

* Company returned $2.2 bln to shareholders in FY25 through dividends and share repurchases

* BD issues FY26 guidance with adjusted EPS expected between $14.75 and $15.05

Outlook

* Company expects FY26 adjusted diluted EPS between $14.75 and $15.05

* BD anticipates low single-digit revenue growth for FY26

Result Drivers

* BD MEDICAL GROWTH - Strong performance in Advanced Patient Monitoring, aided by acquisition from Edwards Lifesciences

* DIAGNOSTIC SOLUTIONS RECOVERY - Diagnostic Solutions unit returned to positive growth with improved product utilization

* INTERVENTIONAL GROWTH - Urology and Critical Care unit saw double-digit growth, driven by PureWick franchise

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q4 Beat $3.96 $3.92

Adjusted (12

EPS Analysts

)

Q4 EPS $1.72

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy", 9 "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"

* Wall Street's median 12-month price target for Becton Dickinson and Co ( BDX ) is $200.96, about 12.2% above its November 5 closing price of $176.39

* The stock recently traded at 12 times the next 12-month earnings vs. a P/E of 12 three months ago

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)